Reduced circulating sTWEAK levels are associated with metabolic syndrome in elderly individuals at high cardiovascular risk

Cardiovascular Diabetology

Volumn 13, Issue 1, 2014, Pages

  Díaz López, Andrés ^a,b   Bulló, Mònica ^a,b   Chacón, Matilde R ^c   Estruch, Ramón ^b,d   Vendrell, Joan ^c   Díez Espino, Javier ^e   Fitó, Montserrat ^b,f   Corella, Dolores ^g   Salas Salvadó, Jordi ^a,b  

^a INSTITUT D INVESTIGACIÓ SANITÀRIA PERE VIRGILI IISPV   (Spain)

^b INSTITUTO DE SALUD CARLOS III   (Spain)

^c HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e Primary Health Care Centre of Tafalla   (Spain)

^f HOSPITAL DEL MAR   (Spain)

^g UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Biomarkers; Cardiovascular risk; Insulin resistance; Metabolic syndrome; STWEAK

Indexed keywords

ALBUMIN; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; SOLUBLE TUMOR NECROSIS FACTOR LIKE WEAK INDUCER OF APOPTOSIS PROTEIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ABDOMINAL OBESITY; ADULT; AGED; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CARDIOVASCULAR RISK; CREATININE URINE LEVEL; CROSS-SECTIONAL STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FAMILY HISTORY; FEMALE; FOOD FREQUENCY QUESTIONNAIRE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PHYSICAL ACTIVITY; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; SMOKING HABIT; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTORS;

EID: 84898600172     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-13-51     Document Type: Article

References (44)

1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL. TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 1997, 272(51):32401-32410. 10.1074/jbc.272.51.32401, 9405449.
2. Sanchez-Niño MD, Benito-Martin A, Gonçalves S, Sanz AB, Ucero AC, Izquierdo MC, Ramos AM, Berzal S, Selgas R, Ruiz-Ortega M, Egido J, Ortiz A. TNF superfamily: a growing saga of kidney injury modulators. Mediators Inflamm 2010, doi:10.1155/2010/182958.
3. Wiley SR, Winkles JA. TWEAK, a member of the TNF superfamily, is a multifunctional cytokine that binds the TweakR/Fn14 receptor. Cytokine Growth Factor Rev 2003, 14(3-4):241-249.
4. Winkles JA. The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 2008, 7(5):411-425. 10.1038/nrd2488, 3018765, 18404150.
5. Blanco-Colio LM, Martin-Ventura JL, Munoz-Garcia B, Orbe J, Paramo JA, Michel JB, Ortiz A, Meilhac O, Egido J. Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 2007, 27(4):916-922. 10.1161/01.ATV.0000258972.10109.ff, 17272745.
6. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N. Decreased soluble TWEAK levels predict an adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 2009, 11(11):1050-1056. 10.1093/eurjhf/hfp139, 19875405.
7. Jelic-Ivanovic Z, Bujisic N, Spasic S, Bogavac-Stanojevic N, Spasojevic-Kalimanovska V, Kotur-Stevuljevic J. Circulating sTWEAK improves the prediction of coronary artery disease. Clin Biochem 2009, 42(13-14):1381-1386.
8. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA. Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 2010, 211(1):322-326. 10.1016/j.atherosclerosis.2010.02.016, 20303491.
9. Moreno JA, Dejouvencel T, Labreuche J, Smadja DM, Dussiot M, Martin-Ventura JL, Egido J, Gaussem P, Emmerich J, Michel JB, Blanco-Colio LM, Meilhac O. Peripheral artery disease is associated with a high CD163/TWEAK plasma ratio. Arterioscler Thromb Vasc Biol 2010, 30(6):1253-1262. 10.1161/ATVBAHA.110.203364, 20299688.
10. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lossner U, Bluher M, Stumvoll M, Fasshauer M. Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 2008, 199(2):440-444. 10.1016/j.atherosclerosis.2007.10.022, 18054361.
11. Karadurmus N, Tapan S, Cakar M, Naharci I, Celik T, Tasci I, Sayin S, Dogan T, Turker T, Erbil MK, Saglam K. Lower plasma soluble TWEAK concentration in patients with newly diagnosed hypertension. Clin Invest Med 2012, 35(1):E20-E26.
12. Yilmaz MI, Carrero JJ, Ortiz A, Martin-Ventura JL, Sonmez A, Saglam M, Yaman H, Yenicesu M, Egido J, Blanco-Colio LM. Soluble TWEAK plasma levels as a novel biomarker of endothelial function in patients with chronic kidney disease. Clin J Am Soc Nephrol 2009, 4(11):1716-1723. 10.2215/CJN.02760409, 2774962, 19820131.
13. Urbonaviciene G, Martin-Ventura JL, Lindholt JS, Urbonavicius S, Moreno JA, Egido J, Blanco-Colio LM. Impact of soluble TWEAK and CD163/TWEAK ratio on long-term cardiovascular mortality in patients with peripheral arterial disease. Atherosclerosis 2011, 219(2):892-899. 10.1016/j.atherosclerosis.2011.09.016, 21962403.
14. Hassan SB, El-demery AB, Ahmed AI, Abukhalil RE. Soluble TWEAK and cardiovascular morbidity and mortality in chronic kidney disease patients. Arab J Nephrol Transplant 2012, 5(1):27-32.
15. Llaurado G, Gonzalez-Clemente JM, Maymo-Masip E, Subias D, Vendrell J, Chacon MR. Serum Levels of TWEAK and Scavenger Receptor CD163 in Type 1 Diabetes Mellitus: Relationship with Cardiovascular Risk Factors. A case-control Study. PLoS One 2012, 7(8):e43919. 10.1371/journal.pone.0043919, 3427173, 22937125.
16. Diaz-Lopez A, Maymo-Masip E, Bullo M, Chacon MR, Martinez-Gonzalez MA, Estruch R, Vendrell J, Basora J, Diez-Espino J, Covas MI, Salas-Salvado J. Serum sTWEAK concentrations and risk of developing type 2 diabetes in a high cardiovascular risk population: a nested case-control study. J Clin Endocrinol Metab 2013, 98(8):3482-3490. 10.1210/jc.2013-1848, 23760626.
17. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation 2005, 111(11):1448-1454. 10.1161/01.CIR.0000158483.13093.9D, 15781756.
18. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, Gómez-Gracia E, Ruiz Gutiérrez V, Fiol M, Lapetra J, Lamuela-Raventos RM, Serra-Majem L, Pintó X, Basora J, Muñoz MA, Sorlí JV, Martínez JA, Martínez-González MA, . PREDIMED Study Investigators Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med 2013, 368(14):1279-1290. 10.1056/NEJMoa1200303, 23432189, PREDIMED Study Investigators.
19. Fernandez-Ballart JD, Pinol JL, Zazpe I, Corella D, Carrasco P, Toledo E, Perez-Bauer M, Martinez-Gonzalez MA, Salas-Salvado J, Martin-Moreno JM. Relative validity of a semi-quantitative food-frequency questionnaire in an elderly Mediterranean population of Spain. Br J Nutr 2010, 103(12):1808-1816. 10.1017/S0007114509993837, 20102675.
20. Elosua R, Marrugat J, Molina L, Pons S, Pujol E. Validation of the Minnesota leisure time physical activity questionnaire in Spanish men. The MARATHOM investigators. Am J Epidemiol 1994, 139(12):1197-1209.
21. Redon J, Coca A. Guidelines for the diagnosis, evaluation and treatment of hypertension: the point of view of the Spanish Society of Hypertension. Med Clin (Barc) 2003, 121(19):739-740. 10.1016/S0025-7753(03)74080-9, 14678696.
22. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, . CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration) A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150(9):604-612. 10.7326/0003-4819-150-9-200905050-00006, 2763564, 19414839, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration).
23. Alberti K, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart J, James WPT, Loria CM, Smith SC. Harmonizing the metabolic syndrome a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645. 10.1161/CIRCULATIONAHA.109.192644, 19805654.
24. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49(4):403-414. 10.1016/j.jacc.2006.09.032, 17258085.
25. Yilmaz MI, Sonmez A, Ortiz A, Saglam M, Kilic S, Eyileten T, Caglar K, Oguz Y, Vural A, Çakar M. Soluble TWEAK and PTX3 in nondialysis CKD patients: impact on endothelial dysfunction and cardiovascular outcomes. Clin J Am Soc Nephrol 2011, 6(4):785-792. 10.2215/CJN.09231010, 3069370, 21330486.
26. Vendrell J, Maymo-Masip E, Tinahones F, Garcia-Espana A, Megia A, Caubet E, Garcia-Fuentes E, Chacon MR. Tumor necrosis-like weak inducer of apoptosis as a proinflammatory cytokine in human adipocyte cells: up-regulation in severe obesity is mediated by inflammation but not hypoxia. J Clin Endocrinol Metab 2010, 95(6):2983-2992. 10.1210/jc.2009-2481, 20382683.
27. Maymó-Masip E, Fernández-Veledo S, García-España A, Vázquez-Carballo A, Tinahones FJ, García-Fuentes E, Garrido-Sanchez L, Rodríguez MM, Vendrell J, Chacón MR. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery May affect adipocyte-cytokine production induced by TNFα. J Clin Endocrinol Metab 2013, 98(8):E1323-E1333. 10.1210/jc.2012-4177, 23783093.
28. Tiller G, Fischer-Posovszky P, Laumen H, Finck A, Skurk T, Keuper M, Brinkmann U, Wabitsch M, Link D, Hauner H. Effects of TWEAK (TNF superfamily member 12) on differentiation, metabolism, and secretory function of human primary preadipocytes and adipocytes. Endocrinology 2009, 150(12):5373-5383. 10.1210/en.2009-0488, 19887572.
29. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, LeBlanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E. TWEAK attenuates the transition from innate to adaptive immunity. Cell 2005, 123(5):931-944. 10.1016/j.cell.2005.09.022, 16325585.
30. Vita JA, Keaney JF. Endothelial function a barometer for cardiovascular risk?. Circulation 2002, 106(6):640-642. 10.1161/01.CIR.0000028581.07992.56, 12163419.
31. Chacon MR, Richart C, Gomez JM, Megia A, Vilarrasa N, Fernandez-Real JM, Garcia-Espana A, Miranda M, Masdevall C, Ricard W, Caubet E, Soler J, Vendrell J. Expression of TWEAK and its receptor Fn14 in human subcutaneous adipose tissue. Relationship with other inflammatory cytokines in obesity. Cytokine 2006, 33(3):129-137. 10.1016/j.cyto.2005.12.005, 16503147.
32. Bover LC, Cardo-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R. A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 2007, 178(12):8183-8194.
33. Fjeldborg K, Christiansen T, Bennetzen M, Møller HJ, Pedersen SB, Richelsen B. The macrophage specific serum marker, soluble CD163, is increased in obesity and reduced after dietary induced weight loss. Obesity 2013, doi:10.1002/oby.20376. [Epub ahead of print].
34. Al-Daghri NM, Al-Attas OS, Bindahman LS, Alokail MS, Alkharfy KM, Draz HM, Yakout S, McTernan PG, Sabico S, Chrousos GP. Soluble CD163 is associated with body mass index and blood pressure in hypertensive obese Saudi patients. Eur J Clin Invest 2012, 42(11):1221-1226. 10.1111/j.1365-2362.2012.02714.x, 22946776.
35. Valdivielso JM, Coll B, Martín-Ventura JL, Moreno JA, Egido J, Fernández E, Blanco-Colio LM. Soluble TWEAK is associated with atherosclerotic burden in patients with chronic kidney disease. J Nephrol 2013, 28:0. doi:10.5301/jn.5000245. [Epub ahead of print].
36. Tirosh A, Shai I, Tekes-Manova D, Israeli E, Pereg D, Shochat T, Kochba I, Rudich A. Normal fasting plasma glucose levels and type 2 diabetes in young men. N Engl J Med 2005, 353(14):1454-1462. 10.1056/NEJMoa050080, 16207847.
37. Feng F, Wang L, Albanese N, Holmes A, Xia P. Tumor necrosis factor-like weak inducer of apoptosis attenuates the action of insulin in hepatocytes. Endocrinology 2008, 149(4):1505-1513. 10.1210/en.2007-1119, 18174283.
38. Chu CS, Lee KT, Cheng KH, Lee MY, Kuo HF, Lin TH, Su HM, Voon WC, Sheu SH, Lai WT. Postchallenge responses of nitrotyrosine and TNF-alpha during 75-g oral glucose tolerance test are associated with the presence of coronary artery diseases in patients with prediabetes. Cardiovasc Diabetol 2012, 11:21. 10.1186/1475-2840-11-21, 3316140, 22397368.
39. Vazquez-Carballo A, Ceperuelo-Mallafré V, Chacon MR, Maymo-Masip E, Lorenzo M, Porras A, Vendrell J, Fernandez-Veledo S. Tweak prevents TNF-α-induced insulin resistance through PP2A activation in human adipocytes. Am J Physiol Endocrinol Metab 2013, 305(1):E101-112. 10.1152/ajpendo.00589.2012, 23651848.
40. Leguisamo NM, Lehnen AM, Machado UF, Okamoto MM, Markoski MM, Pinto GH, Schaan BD. GLUT4 content decreases along with insulin resistance and high levels of inflammatory markers in rats with metabolic syndrome. Cardiovasc Diabetol 2012, 11:100. 10.1186/1475-2840-11-100, 3439702, 22897936.
41. Fernández-Veledo S, Vila-Bedmar R, Nieto-Vazquez I, Lorenzo M. c-Jun N-terminal kinase 1/2 activation by tumor necrosis factor-α induces insulin resistance in human visceral but not subcutaneous adipocytes: reversal by liver X receptor agonists. J Clin Endocrinol Metab 2009, 94(9):3583-3593. 10.1210/jc.2009-0558, 19567513.
42. Yamana J, Morand EF, Manabu T, Sunahori K, Takasugi K, Makino H, Yamamura M. Inhibition of TNF-induced IL-6 by the TWEAK-Fn14 interaction in rheumatoid arthritis fibroblast like synoviocytes. Cell Immunol 2012, 272(2):293-298. 10.1016/j.cellimm.2011.09.004, 22055894.
43. Echeverry R, Wu F, Haile WB, Wu J, Yepes M. The cytokine tumor necrosis factor-like weak inducer of apoptosis and its receptor fibroblast growth factor-inducible 14 have a neuroprotective effect in the central nervous system. J Neuroinflammation 2012, 9(1):45. 10.1186/1742-2094-9-45, 3311607, 22394384.
44. Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, Henkler F, Gohlke F, Kneitz C, Wajant H. TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling. Cell Death Differ 2009, 16(11):1445-1459. 10.1038/cdd.2009.80, 19557010.